New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
20:25 EDTCOCO, COCO, NS, NS, LII, LII, BIP, BIP, NDAQ, NDAQ, LVLT, LVLT, GRA, GRA, CCE, CCE, BEAM, BEAM, RL, RL, MMP, MMP, HUM, HUM, EL, EL, CTSH, CTSH, AGN, AGN, ADP, ADP, TWX, TWX, MRK, MRKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Merck (MRK), consensus 88c; Time Warner (TWX), consensus $1.15; Automatic Data Processing (ADP), consensus 77c; Allergan (AGN), consensus $1.34; Cognizant (CTSH), consensus $1.06; Estee Lauder (EL), consensus $1.06; Humana (HUM), consensus 94c; Magellan Midstream (MMP), consensus 81c; Ralph Lauren (RL), consensus $2.51; Beam (BEAM), consensus 72c; Coca-Cola Enterprises (CCE), consensus 52c; W.R. Grace (GRA), consensus $1.19; Level 3 (LVLT), consensus 3c; Nasdaq (NDAQ), consensus 67c; Brookfield Infrastructure Partners (BIP), consensus 35c; Lazard (LAZ), consensus 61c; Arrow Electronics(ARW), consensus $1.62; Lennox International (LII), consensus 74c; NuStar Energy (NS), consensus 35c; Corinthian Colleges (COCO), consensus 2c.
News For MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO From The Last 14 Days
Check below for free stories on MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
July 16, 2014
07:59 EDTAGNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:43 EDTTWXDiscovery volatility expected to move on Time Warner rejecting 21st Century Fox
Discovery (DISCA) volatility expected to move after Time Warner (TWX) rejected an $80B offer from 21st Century Fox, (FOXA). Overall option implied volatility of 25 is near its 26-week average of according to Track Data, suggesting non-directional price movement. Discovery is expected to release of Q2 results on July 31.
07:30 EDTTWXTime Warner turned down $80B offer from 21st Century Fox, NYT says
Subscribe for More Information
07:25 EDTTWX21st Century Fox volatility expected to move on Time Warner rejecting $80B offer
Subscribe for More Information
07:23 EDTTWXTime Warner volatility expected to move,rejects $80B offer from 21st Century Fox
Subscribe for More Information
07:12 EDTTWXTime Warner rejected $80B offer from 21st Century Fox, CNBC reports
Time Warner (TWX) has formally rejected an $80B takeover offer from Rupert Murdoch's 21st Century Fox (FOXA), CNBC's Andrew Ross Sorkin reports, citing sources. The deal valued Time Warner at $85 per share and included 60% non-voting stock and 40% cash, Sorkin added. Fox would raise $24B in financing for the deal, he noted. Fox also planned on spinning off its CNN unit in an attempt to appease regulators, the reporter said. Rupert Murdoch remains "determined" to buy Time Warner, Sorkin noted, believing a combination would generate at least $1B in synergies. Time Warner has hired Citigroup and others following receipt of 21st Century Fox's offer, Sorkin added. Shares of Time Warner rallied 13% to $79.97 in pre-open trading following Sorkin's report. The stock closed yesterday down 67c to $71.01.
07:06 EDTTWXTime Warner rejected $80B offer from 21st Century Fox, CNBC reports
07:04 EDTTWXRupert Murdoch 'determined' to own Time Warner, CNBC reports
07:04 EDTTWXTime Warner hired Citigroup, others after 21st Century Fox offer, CNBC says
Subscribe for More Information
07:02 EDTTWXTime Warner rejected $85/share offer from 21st Century Fox, CNBC says
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRK, AGNPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTTWXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adecogro (AGRO) downgraded to Underperform from Neutral at BofA/Merrill... Campbell Soup (CPB) downgraded to Sell from Neutral at Goldman... Credicorp (BAP) downgraded to Neutral from Overweight at JPMorgan... El Paso Pipeline (EPB) downgraded to Neutral from Buy at Citigroup... Kellogg (K) downgraded to Sell from Neutral at Goldman... Kodiak Oil & Gas (KOG) downgraded to Market Perform from Outperform at BMO Capital... Lexmark (LXK) downgraded at Bernstein... Maxim Integrated (MXIM) downgraded to Equal Weight from Overweight at Barclays... Republic Airways (RJET) downgraded to Underperform from Neutral at BofA/Merrill... Sasol (SSL) downgraded to Neutral from Buy at Citigroup... Time Warner (TWX) downgraded to Equal Weight from Overweight at Evercore.
09:59 EDTCOCOApollo Education discloses new Department of Education review
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
07:24 EDTLVLTMicrosoft to hold a conference
MSFT Worldwide Partner Conference to be held in Washington, D.C. on July 13-17.
06:43 EDTTWXTime Warner looks for NBA programming deal renewal, Bloomberg says
Time Warner (TWC) and Disney's (DIS) ESPN are looking to renew the last big U.S. sports agreement with the National Basketball Association thatís up for grabs until 2021, according Reuters, citing people familiar with the talks. Time Warner and Disney, which divvy-up airing the games, pay the league an average total of $930M annually. Reference Link
06:36 EDTTWXNBA seeks to double TV-rights fees from Disney, Time Warner, WSJ reports
Subscribe for More Information
06:06 EDTTWXTime Warner downgraded to Equal Weight from Overweight at Evercore
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use